Dermatology specialist Galderma (SWX:GALD) on Thursday announced the publication of positive Phase III OLYMPIA 1 trial results for nemolizumab in JAMA Dermatology.
The drug demonstrated significant improvements in itch and skin lesions in patients with moderate-to-severe prurigo nodularis.
Nemolizumab, a first-in-class monoclonal antibody targeting IL-31, showed rapid and sustained relief from itch and sleep disturbance. The drug has already been approved by the US Food and Drug Administration (FDA) for the treatment of prurigo nodularis in adults and is currently under review by regulatory authorities worldwide for both prurigo nodularis and atopic dermatitis.
Armata Pharmaceuticals announces receipt of FDA Breakthrough Therapy Designation for AP-SA02
GSK reports positive Jideytro data supporting potential first-line lung cancer use
Eloxx Pharmaceuticals commences Phase 2b study of exaluren
Meant Health announces expansion of telehealth access for FDA-approved GLP-1 prescriptions
US FDA grants orphan drug designation for Lundbeck's asedebart
Renova Pharmaceuticals launches first three US generic products
FDA grants Priority Review to Genentech's Enspryng for MOGAD
CordenPharma increases aseptic fill-finish capacity
Biophytis expands BIO101 obesity study to assess weight regain
THX Pharma secures European patent for Batten-1 in juvenile Batten disease
Etcamah–CDK4/6 inhibitor combination approved in US for ESR1-mutated HR-positive breast cancer
Guardant Health wins FDA approval for Guardant360 CDx in advanced breast cancer
Agilent launches S540MD slide scanner system in US
Kali Therapeutics' KT501 Investigational New Drug application cleared by US FDA